These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. CD79B and MYD88 mutations in diffuse large B-cell lymphoma. Kim Y; Ju H; Kim DH; Yoo HY; Kim SJ; Kim WS; Ko YH Hum Pathol; 2014 Mar; 45(3):556-64. PubMed ID: 24444466 [TBL] [Abstract][Full Text] [Related]
6. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma. Choi JW; Kim Y; Lee JH; Kim YS Hum Pathol; 2013 Jul; 44(7):1375-81. PubMed ID: 23380077 [TBL] [Abstract][Full Text] [Related]
7. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma. Takeuchi T; Yamaguchi M; Kobayashi K; Miyazaki K; Tawara I; Imai H; Ono R; Nosaka T; Tanaka K; Katayama N Cancer; 2017 Apr; 123(7):1166-1173. PubMed ID: 27915469 [TBL] [Abstract][Full Text] [Related]
8. Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma. Zheng M; Perry AM; Bierman P; Loberiza F; Nasr MR; Szwajcer D; Del Bigio MR; Smith LM; Zhang W; Greiner TC Neuropathology; 2017 Dec; 37(6):509-516. PubMed ID: 28856744 [TBL] [Abstract][Full Text] [Related]
9. Clinical significance of MYD88 non-L265P mutations in diffuse large B-cell lymphoma. Xie J; Shen X; Shi Q; Yi H; Ouyang B; Zhang Z; Gu Y; Dong L Hematol Oncol; 2022 Dec; 40(5):885-893. PubMed ID: 36053490 [TBL] [Abstract][Full Text] [Related]
10. MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma. Aggarwal V; Das A; Bal A; Srinivasan R; Das R; Prakash G; Malhotra P; Varma S Appl Immunohistochem Mol Morphol; 2019 Apr; 27(4):311-318. PubMed ID: 29734251 [TBL] [Abstract][Full Text] [Related]
11. Morphologic Patterns and the Correlation With MYD88 L265P, CD79B Mutations in Primary Adrenal Diffuse Large B-Cell Lymphoma. Chen Z; Zou Y; Liu W; Guan P; Tao Q; Xiang C; Zhang W; Ye Y; Yan J; Zhao S Am J Surg Pathol; 2020 Apr; 44(4):444-455. PubMed ID: 31609782 [TBL] [Abstract][Full Text] [Related]
12. B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice. Knittel G; Liedgens P; Korovkina D; Seeger JM; Al-Baldawi Y; Al-Maarri M; Fritz C; Vlantis K; Bezhanova S; Scheel AH; Wolz OO; Reimann M; Möller P; López C; Schlesner M; Lohneis P; Weber AN; Trümper L; ; Staudt LM; Ortmann M; Pasparakis M; Siebert R; Schmitt CA; Klatt AR; Wunderlich FT; Schäfer SC; Persigehl T; Montesinos-Rongen M; Odenthal M; Büttner R; Frenzel LP; Kashkar H; Reinhardt HC Blood; 2016 Jun; 127(22):2732-41. PubMed ID: 27048211 [TBL] [Abstract][Full Text] [Related]
13. The Prevalence of MYD88 L265P and TNFAIP3 Mutations and Their Correlations with Clinico-Hematological Profile in Egyptian Patients with Diffuse Large B Cell Lymphoma. Elbaz O; Shaat RM; Abd El Ghaffar HA; Shamaa S; Abdel-Masseih HM; Anber N; Mortada MI Asian Pac J Cancer Prev; 2023 Jul; 24(7):2485-2491. PubMed ID: 37505783 [TBL] [Abstract][Full Text] [Related]
14. Clinicopathological features of 49 primary gastrointestinal diffuse large B-cell lymphoma cases; comparison with location, cell-of-origin, and frequency of MYD88 L265P. Nagakita K; Takata K; Taniguchi K; Miyata-Takata T; Sato Y; Tari A; Ohnishi N; Noujima-Harada M; Omote S; Nakamura N; Iwamuro M; Maeda Y; Okada H; Tanimoto M; Yoshino T Pathol Int; 2016 Aug; 66(8):444-52. PubMed ID: 27439595 [TBL] [Abstract][Full Text] [Related]
15. Disrupting myddosome assembly in diffuse large B‑cell lymphoma cells using the MYD88 dimerization inhibitor ST2825. Wang X; Tan Y; Huang Z; Huang N; Gao M; Zhou F; Hu J; Feng W Oncol Rep; 2019 Nov; 42(5):1755-1766. PubMed ID: 31432184 [TBL] [Abstract][Full Text] [Related]
16. High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type. Pham-Ledard A; Beylot-Barry M; Barbe C; Leduc M; Petrella T; Vergier B; Martinez F; Cappellen D; Merlio JP; Grange F JAMA Dermatol; 2014 Nov; 150(11):1173-9. PubMed ID: 25055137 [TBL] [Abstract][Full Text] [Related]
17. HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization. Boudesco C; Verhoeyen E; Martin L; Chassagne-Clement C; Salmi L; Mhaidly R; Pangault C; Fest T; Ramla S; Jardin F; Wolz OO; Weber ANR; Garrido C; Jego G Blood; 2018 Aug; 132(5):510-520. PubMed ID: 29871863 [TBL] [Abstract][Full Text] [Related]
18. Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma. Bohers E; Mareschal S; Bouzelfen A; Marchand V; Ruminy P; Maingonnat C; Ménard AL; Etancelin P; Bertrand P; Dubois S; Alcantara M; Bastard C; Tilly H; Jardin F Genes Chromosomes Cancer; 2014 Feb; 53(2):144-53. PubMed ID: 24327543 [TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis. Lee JH; Jeong H; Choi JW; Oh H; Kim YS Sci Rep; 2017 May; 7(1):1785. PubMed ID: 28496180 [TBL] [Abstract][Full Text] [Related]
20. Development of high-resolution melting analysis for the detection of the MYD88 L265P mutation. Wang CZ; Lin J; Qian J; Shao R; Xue D; Qian W; Xiao GF; Deng ZQ; Yang J; Li Y; Chen XX Clin Biochem; 2013 Mar; 46(4-5):385-7. PubMed ID: 23178471 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]